Related Experiment Video
Updated: Feb 19, 2026
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Identification of antigenic peptides from novel renal cancer stem-like cell antigen, DNAJB8
Satoshi Nishizawa1, Yoshihiko Hirohashi2, Hiroki Kusumoto3
1Department of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama 641-8509, Japan.
Objectives:
To identify antigenic peptides of cancer stem-like cells (CSCs) antigen, DNAJB8, and establish a mouse CSCs-targeting immunotherapy model.
Materials And Methods:
To induce DNAJB8-specific immune reaction, we stimulated human CD8+ lymphocytes with antigen-presenting cells pulsed with a cocktail of three candidate HLA-A*24:02 restricted peptides and assessed peptide specific human cytotoxic T lymphocytes (CTLs) induction. One of the antigenic peptides showed identical amino acid sequence as corresponding mouse DNAJB8. We evaluated CTL induction with the peptide immunization in mouse model.
Results:
We confirmed peptide-specific interferon-γ secretions and cytotoxic activities of induced human CTLs. In vivo immunization with the peptide to mice, peptide-specific CTL response could be observed in mouse CD8+ T cells. Furthermore, immunization with the peptide showed significant anti-tumor effects compared with negative controls.
Conclusion:
DNAJB8-derived peptide is a novel candidate for CSCs-targeting immunotherapy, and mouse models can be used to evaluate CSCs-targeting immunotherapy.
Insights
Researchers identified a DNAJB8-derived peptide as a promising target for cancer stem-like cell (CSC) immunotherapy. A mouse model demonstrated the peptide
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Cancer stem-like cells (CSCs) are crucial drivers of tumor initiation and progression.
- Targeting CSCs is a key strategy for effective cancer immunotherapy.
- DNAJB8 is identified as a potential CSC antigen.
Purpose of the Study:
- To identify antigenic peptides derived from the DNAJB8 antigen.
- To establish a preclinical mouse model for evaluating CSC-targeting immunotherapy.
Main Methods:
- Human CD8+ lymphocytes were stimulated with antigen-presenting cells pulsed with candidate peptides.
- Peptide-specific cytotoxic T lymphocytes (CTLs) induction was assessed.
- Immunization and anti-tumor effects were evaluated in a mouse model.
Main Results:
- A DNAJB8-derived peptide was identified and showed cross-reactivity with mouse DNAJB8.
- Induced human CTLs exhibited peptide-specific cytotoxic activity and interferon-γ secretion.
- In vivo peptide immunization in mice elicited peptide-specific CTL responses and demonstrated significant anti-tumor effects.
Conclusions:
- DNAJB8-derived peptides represent a novel therapeutic candidate for CSC-targeting immunotherapy.
- The developed mouse model is suitable for evaluating the efficacy of CSC-targeting immunotherapies.
